BioMarin's $990 Million Q2 Beat Raised the Bar: $1 Billion VOXZOGO Now Must Back the Growth Story

The beat improved the setup, but it also raised the bar

A strong quarter is not a verdict. It is a higher bar.

BioMarin's second quarter reinforced the idea that 2026 is still on a stronger trajectory, with Q2 revenue of $990 million and adjusted EPS of $1.20 both beating expectations. The company also reiterated the full-year range it had set earlier in the year at $3.825 billion-$3.925 billion. Management had already lifted 2026 VOXZOGO revenue guidance to at least $1 billion, so the near-term revenue base now looks firmer than it did a quarter ago.

That also means expectations rose with the quarter. When a company beats estimates and holds an elevated outlook, investors start looking beyond the headline to the next few quarters. Holding the new range should be viewed as solid execution; beating it would strengthen the case further. If momentum fades after such a clean quarter, any earlier relief rally could cool off quickly.

Portfolio breadth, not just VOXZOGO, improved the mix

The more constructive change was in the composition of growth.

The Amicus acquisition added to BioMarin's growth and is expected to deliver about $220 million in annual cost synergies, while also expanding the company's commercial base. That matters because a business built around several medicines growing together is generally less dependent on any single product than a one-drug story. On the earnings transcript, management described the expanded group as a broader commercial base, led by its metabolic conditions unit.

Several assets are contributing at the same time

The quarter was not about one center of gravity carrying the whole portfolio. PALYNZIQ rose 27%, while the newer Amicus assets showed strong pro forma growth, and VOXZOGO continued to expand as well. That points to a broader revenue base rather than a portfolio where one asset has to do everything.

This broader mix arrived even with full-year VOXZOGO revenue guidance raised to at least $1 billion. The more balanced takeaway is not that BioMarin needs one drug to carry the story. It is that VOXZOGO remains a major growth engine while other assets are helping broaden the platform.

Profitability held up during integration

What stood out was not just revenue growth, but the fact that profitability remained healthy during a period of integration.

Operating margin stayed strong despite acquisition costs

Non-GAAP operating margin reached 36.4%, showing that the company is still generating solid profitability even as it absorbs acquisition-related costs and invests in its pipeline. That matters because growth is more credible when it shows up alongside margin resilience, especially during a period of consolidation.

The longer-term payoff depends on execution

Management said it would provide a longer-term integration update next quarter. That points to a more important test ahead: whether BioMarin can translate a larger portfolio and expected synergies into steadier operating performance through the rest of 2026. For now, the quarter improved the setup, but sustained execution remains the real next checkpoint.